annual accounts payable:
$789.50M+$182.90M(+30.15%)Summary
- As of today (August 23, 2025), REGN annual accounts payable is $789.50 million, with the most recent change of +$182.90 million (+30.15%) on December 31, 2024.
- During the last 3 years, REGN annual accounts payable has risen by +$225.50 million (+39.98%).
- REGN annual accounts payable is now at all-time high.
Performance
REGN Accounts payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly accounts payable:
$723.90M+$18.40M(+2.61%)Summary
- As of today (August 23, 2025), REGN quarterly accounts payable is $723.90 million, with the most recent change of +$18.40 million (+2.61%) on June 30, 2025.
- Over the past year, REGN quarterly accounts payable has increased by +$162.20 million (+28.88%).
- REGN quarterly accounts payable is now -8.31% below its all-time high of $789.50 million, reached on December 31, 2024.
Performance
REGN quarterly accounts payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Accounts payable Formula
Accounts Payable = Beginning Accounts Payable + Purchases on Credit − Payments to Suppliers
REGN Accounts payable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +30.1% | +28.9% |
| 3 y3 years | +40.0% | +35.5% |
| 5 y5 years | +88.8% | +90.5% |
REGN Accounts payable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +40.0% | -8.3% | +45.6% |
| 5 y | 5-year | at high | +88.8% | -8.3% | +90.5% |
| alltime | all time | at high | >+9999.0% | -8.3% | >+9999.0% |
REGN Accounts payable History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2025 | - | $723.90M(+2.6%) |
| Mar 2025 | - | $705.50M(-10.6%) |
| Dec 2024 | $789.50M(+30.2%) | $789.50M(+58.8%) |
| Sep 2024 | - | $497.30M(-11.5%) |
| Jun 2024 | - | $561.70M(-16.3%) |
| Mar 2024 | - | $671.30M(+10.7%) |
| Dec 2023 | $606.60M(+3.0%) | $606.60M(+13.0%) |
| Sep 2023 | - | $536.60M(-2.0%) |
| Jun 2023 | - | $547.30M(-8.7%) |
| Mar 2023 | - | $599.50M(+1.7%) |
| Dec 2022 | $589.20M(+4.5%) | $589.20M(+10.0%) |
| Sep 2022 | - | $535.60M(+0.3%) |
| Jun 2022 | - | $534.20M(+13.6%) |
| Mar 2022 | - | $470.30M(-16.6%) |
| Dec 2021 | $564.00M(+18.6%) | $564.00M(+32.1%) |
| Sep 2021 | - | $427.00M(-10.3%) |
| Jun 2021 | - | $476.00M(-12.3%) |
| Mar 2021 | - | $542.90M(+14.2%) |
| Dec 2020 | $475.50M(+13.7%) | $475.50M(+7.3%) |
| Sep 2020 | - | $443.10M(+16.6%) |
| Jun 2020 | - | $380.10M(+9.3%) |
| Mar 2020 | - | $347.80M(-16.8%) |
| Dec 2019 | $418.10M(+91.6%) | $418.10M(+24.6%) |
| Sep 2019 | - | $335.60M(+37.5%) |
| Jun 2019 | - | $244.00M(+1.8%) |
| Mar 2019 | - | $239.60M(+9.8%) |
| Dec 2018 | $218.20M(+22.5%) | $218.20M(+26.6%) |
| Sep 2018 | - | $172.36M(+0.3%) |
| Jun 2018 | - | $171.91M(-17.2%) |
| Mar 2018 | - | $207.61M(+16.5%) |
| Dec 2017 | $178.18M(+32.0%) | $178.18M(+15.7%) |
| Sep 2017 | - | $153.95M(+1.7%) |
| Jun 2017 | - | $151.37M(+6.7%) |
| Mar 2017 | - | $141.80M(+5.1%) |
| Dec 2016 | $134.98M(-4.2%) | $134.98M(+8.4%) |
| Sep 2016 | - | $124.50M(+22.4%) |
| Jun 2016 | - | $101.72M(-15.7%) |
| Mar 2016 | - | $120.59M(-14.4%) |
| Dec 2015 | $140.96M(+41.7%) | $140.96M(+31.8%) |
| Sep 2015 | - | $106.92M(-17.8%) |
| Jun 2015 | - | $130.02M(+43.5%) |
| Mar 2015 | - | $90.60M(-9.0%) |
| Dec 2014 | $99.51M(+60.7%) | $99.51M(+110.2%) |
| Sep 2014 | - | $47.34M(+0.2%) |
| Jun 2014 | - | $47.23M(+44.5%) |
| Mar 2014 | - | $32.69M(-47.2%) |
| Dec 2013 | $61.94M(+59.1%) | $61.94M(+98.6%) |
| Sep 2013 | - | $31.19M(+27.8%) |
| Jun 2013 | - | $24.42M(-1.3%) |
| Mar 2013 | - | $24.73M(-36.5%) |
| Dec 2012 | $38.93M(+40.4%) | $38.93M(+77.4%) |
| Sep 2012 | - | $21.94M(-14.5%) |
| Jun 2012 | - | $25.67M(+1.1%) |
| Mar 2012 | - | $25.39M(-8.5%) |
| Dec 2011 | $27.74M(+55.4%) | $27.74M(+33.9%) |
| Sep 2011 | - | $20.71M(-44.0%) |
| Jun 2011 | - | $36.97M(+95.5%) |
| Mar 2011 | - | $18.91M(+6.0%) |
| Dec 2010 | $17.84M(-10.0%) | $17.84M(-21.0%) |
| Sep 2010 | - | $22.58M(+45.4%) |
| Jun 2010 | - | $15.53M(-4.1%) |
| Mar 2010 | - | $16.19M(-18.3%) |
| Dec 2009 | $19.82M(+23.4%) | $19.82M(+19.4%) |
| Sep 2009 | - | $16.61M(+27.4%) |
| Jun 2009 | - | $13.03M(-26.7%) |
| Mar 2009 | - | $17.78M(+10.7%) |
| Dec 2008 | $16.07M | $16.07M(+21.8%) |
| Sep 2008 | - | $13.19M(-17.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2008 | - | $16.07M(+52.6%) |
| Mar 2008 | - | $10.53M(-19.1%) |
| Dec 2007 | $13.02M(+199.4%) | $13.02M(+144.3%) |
| Sep 2007 | - | $5.33M(-71.3%) |
| Jun 2007 | - | $18.55M(+286.0%) |
| Mar 2007 | - | $4.80M(+10.5%) |
| Dec 2006 | $4.35M(+3.5%) | $4.35M(+18.9%) |
| Sep 2006 | - | $3.66M(+28.8%) |
| Jun 2006 | - | $2.84M(-24.4%) |
| Mar 2006 | - | $3.76M(-10.6%) |
| Dec 2005 | $4.20M(-4.6%) | $4.20M(+21.8%) |
| Sep 2005 | - | $3.45M(+4.7%) |
| Jun 2005 | - | $3.30M(+7.4%) |
| Mar 2005 | - | $3.07M(-30.3%) |
| Dec 2004 | $4.41M(+13.6%) | $4.41M(-15.0%) |
| Sep 2004 | - | $5.18M(+46.1%) |
| Jun 2004 | - | $3.55M(-81.3%) |
| Mar 2004 | - | $18.95M(+388.6%) |
| Dec 2003 | $3.88M(-70.8%) | $3.88M(+0.5%) |
| Sep 2003 | - | $3.86M(-3.1%) |
| Jun 2003 | - | $3.98M(-58.1%) |
| Mar 2003 | - | $9.52M(-28.4%) |
| Dec 2002 | $13.30M(+342.2%) | $13.30M(+225.1%) |
| Sep 2002 | - | $4.09M(-75.8%) |
| Jun 2002 | - | $16.93M(-0.8%) |
| Mar 2002 | - | $17.07M(+467.6%) |
| Dec 2001 | $3.01M(+16.1%) | $3.01M(-70.3%) |
| Sep 2001 | - | $10.12M(+21.9%) |
| Jun 2001 | - | $8.30M(+3479.3%) |
| Mar 2001 | - | $232.00K(-91.0%) |
| Dec 2000 | $2.59M(-2.0%) | $2.59M(-68.2%) |
| Sep 2000 | - | $8.13M(+6.1%) |
| Jun 2000 | - | $7.67M(+10.8%) |
| Mar 2000 | - | $6.92M(+162.0%) |
| Dec 1999 | $2.64M(+18.8%) | $2.64M(-41.7%) |
| Sep 1999 | - | $4.53M(-6.7%) |
| Jun 1999 | - | $4.85M(-19.5%) |
| Mar 1999 | - | $6.03M(+171.3%) |
| Dec 1998 | $2.22M(-24.6%) | $2.22M(-49.4%) |
| Sep 1998 | - | $4.39M(-13.5%) |
| Jun 1998 | - | $5.08M(+37.9%) |
| Mar 1998 | - | $3.68M(-21.6%) |
| Dec 1997 | $2.95M(+35.3%) | $4.70M(+14.6%) |
| Sep 1997 | - | $4.10M(-19.6%) |
| Jun 1997 | - | $5.10M(+50.0%) |
| Mar 1997 | - | $3.40M(-22.7%) |
| Dec 1996 | $2.18M(-32.8%) | $4.40M(+4.8%) |
| Sep 1996 | - | $4.20M(0.0%) |
| Jun 1996 | - | $4.20M(-2.3%) |
| Mar 1996 | - | $4.30M(-31.7%) |
| Dec 1995 | $3.24M(+57.9%) | $6.30M(+46.5%) |
| Sep 1995 | - | $4.30M(-6.5%) |
| Jun 1995 | - | $4.60M(+24.3%) |
| Mar 1995 | - | $3.70M(-26.0%) |
| Dec 1994 | $2.05M(-2.4%) | $5.00M(+19.0%) |
| Sep 1994 | - | $4.20M(-34.4%) |
| Jun 1994 | - | $6.40M(+6.7%) |
| Mar 1994 | - | $6.00M(-41.7%) |
| Dec 1993 | $2.10M(+150.8%) | $10.30M(+53.7%) |
| Sep 1993 | - | $6.70M(+28.8%) |
| Jun 1993 | - | $5.20M(+73.3%) |
| Mar 1993 | - | $3.00M(+20.0%) |
| Dec 1992 | $838.80K(-46.8%) | $2.50M(+31.6%) |
| Jun 1992 | - | $1.90M(0.0%) |
| Mar 1992 | - | $1.90M(+18.8%) |
| Dec 1991 | $1.58M | $1.60M(+220.0%) |
| Sep 1991 | - | $500.00K(-37.5%) |
| Jun 1991 | - | $800.00K |
FAQ
- What is Regeneron Pharmaceuticals, Inc. annual accounts payable?
- What is the all time high annual accounts payable for Regeneron Pharmaceuticals, Inc.?
- What is Regeneron Pharmaceuticals, Inc. annual accounts payable year-on-year change?
- What is Regeneron Pharmaceuticals, Inc. quarterly accounts payable?
- What is the all time high quarterly accounts payable for Regeneron Pharmaceuticals, Inc.?
- What is Regeneron Pharmaceuticals, Inc. quarterly accounts payable year-on-year change?
What is Regeneron Pharmaceuticals, Inc. annual accounts payable?
The current annual accounts payable of REGN is $789.50M
What is the all time high annual accounts payable for Regeneron Pharmaceuticals, Inc.?
Regeneron Pharmaceuticals, Inc. all-time high annual accounts payable is $789.50M
What is Regeneron Pharmaceuticals, Inc. annual accounts payable year-on-year change?
Over the past year, REGN annual accounts payable has changed by +$182.90M (+30.15%)
What is Regeneron Pharmaceuticals, Inc. quarterly accounts payable?
The current quarterly accounts payable of REGN is $723.90M
What is the all time high quarterly accounts payable for Regeneron Pharmaceuticals, Inc.?
Regeneron Pharmaceuticals, Inc. all-time high quarterly accounts payable is $789.50M
What is Regeneron Pharmaceuticals, Inc. quarterly accounts payable year-on-year change?
Over the past year, REGN quarterly accounts payable has changed by +$162.20M (+28.88%)